#Taiwan #New Taipei City #Cancer Research #GlycoNex #GNX1021

GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025

GlycoNex, Inc., a biopharma pioneering in glycan-directed cancer immunotherapies, is set to unveil crucial preclinical findings for GNX1021 at the esteemed AACR Annual Meeting 2025.

Scheduled for April 28, 2025, in Chicago, this event represents a significant opportunity for GlycoNex to highlight the potential of GNX1021—a next-generation antibody-drug conjugate (ADC) designed to target branched Lewis B/Y (bLeB/Y) antigens prevalent in gastric cancer and other solid tumors.

The Significance of the Presentation

The acceptance of GNX1021's research presentation at such a prominent venue as the AACR Annual Meeting underscores the high expectations associated with this innovative therapy. Dr. Mei-Chun Yang, the CEO of GlycoNex, expressed her excitement regarding the showcasing of GNX1021, which could provide novel treatment options for gastric cancer—an aggressive form of cancer traditionally met with limited therapeutic avenues.

The forthcoming poster session will concentrate on preclinical data that illustrates both the efficacy and safety of GNX1021 based on rigorous evaluations performed using gastric cancer models. The insights offered during this session aim not only to present the drug's capacity to control tumor growth but also to reaffirm its safety profile.

Details of the Presentation

The specific details of the GNX1021 presentation include:

• - Event: American Association for Cancer Research (AACR) Annual Meeting 2025
• - Session Category: Experimental and Molecular Therapeutics
• - Session Focus: Targeting Growth Factor Receptors and Other Surface Antigens
• - Abstract Title: GNX1021, a novel ADC targeting glycans with branched Lewis B/Y, demonstrated preclinical tumor control activity in gastric cancer models and favorable safety
• - Date & Time: April 28, 2025, at 2:00 PM CDT
• - Location: McCormick Place Convention Center, Poster Section 17, Board 6

About GlycoNex and Its Mission

Founded to confront significant challenges in oncology, GlycoNex is deeply invested in the creation of immunotherapies that directly target glycan structures on cancer cells. The company's lead therapeutic, GNX102, represents a humanized monoclonal antibody designed to tackle irregular sugar molecules that frequently occur in malignancies.

The firm has already made strides with GNX102, completing Phase 1 clinical trials that showcased both safety and early efficacy results that are encouraging for future development.

In addition to GNX102, GlycoNex is working on a wider portfolio of ADCs, each meticulously designed to minimize damage to healthy tissues while effectively targeting malignant cells. This focus on precise treatment represents the future of oncology therapies, gathering anticipation from both the medical community and patients alike.

As GlycoNex prepares to share its work at AACR 2025, the scientific and medical communities will be watching closely, eager to understand how GNX1021 could potentially reshape treatment paradigms for gastric cancer.

For further insights and updates, visit GlycoNex's official site at http://www.glyconex.com.tw.